Skip to main content
Equibles
CLDX logo

CLDX · Celldex Therapeutics, Inc. · Metrics

Track CLDX — free

Use CLDX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CLDX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$31.24 +1.37 (+4.59%) Q4 2021 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$2.35B
Shares
78.55M
Volume · Nov 9 1.59M Avg daily vol (3M) 1.35M

CLDX metrics

84 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$31.24
Market cap
$2.35B

Price action

23 metrics
Price change (1W)
-0.8%
Price change (30D)
-0.1%
Price change (3M)
-28.4%
Price change (6M)
-12.1%
Price change (YTD)
+10.0%
Price change (1Y)
+28.4%
Trailing year
Price change (5Y)
-34.9%
52-week high
$44.87
52-week low
$22.58
Change from 52-week high
-33.4%
Change from 52-week low
+32.3%
Annualized volatility
52.5%
Annualized volatility (3M)
49.2%
Implied volatility (30D)
56.2%
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
1.2
RSI (14D)
47.3
Price vs SMA 50
-9.3%
Price vs SMA 200
-8.8%
Avg volume (3M)
1.34M
Relative volume
0.7
Average dollar volume
$45.01M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
78.55M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
10,801.4×
reciprocal yield 0.0%
EV / EBITDA
—
EV / EBIT
—
P / sales
14,943.6×
reciprocal yield 0.0%
P / book
3.6
reciprocal yield 27.7%
FCF yield
-11.1%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-13.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
2,533.2×
reciprocal yield 0.0%
EV / revenue historical average (5Y)
1,695.5×
reciprocal yield 0.1%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-09-22

Profitability

9 metrics
Gross margin
87.1%
Operating margin
-213,033.8%
Trailing 12 months
Net margin
-196,854.8%
Gross profit (TTM)
—
Operating profit (TTM)
−$334.46M
Net income (TTM)
−$309.06M
Trailing 12 months
Diluted EPS (TTM)
$-4.31
FCF margin
-165,438.9%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.00
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-4.66
EBITDA per diluted share (TTM)
$-4.61
Net income per diluted share (TTM)
$-4.31
Operating cash flow per diluted share (TTM)
$-3.51
Free cash flow per diluted share (TTM)
$-3.62
Capital expenditures per diluted share (TTM)
$0.11
R&D per diluted share (TTM)
$3.96
Stock compensation per diluted share (TTM)
$0.51
Book value per share
$7.92

Growth

11 metrics
Revenue growth YoY
-78.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$157,000
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+18.2%
Year over year · more shares
Revenue CAGR (3Y)
-13.1%
Revenue CAGR (5Y)
-26.9%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-47.6%
Return on assets
-42.8%
Debt / equity
0.0
Current ratio
11.0
EBITDA (TTM)
−$330.73M
Free cash flow (TTM)
−$259.74M
Quick ratio
11.0
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$650.32M
Latest balance sheet
Cash & equivalents
$26.95M
Total assets
$721.53M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$251.97M
Capital expenditures (TTM)
$7.77M
R&D (TTM)
$283.28M
SG&A (TTM)
—
Stock compensation (TTM)
$36.81M
R&D / revenue
180,435.0%
Stock compensation / revenue
23,448.4%

Ownership (13F)

9 metrics
13F filers
260
13F filer change QoQ
+27
Institutional ownership
109.2%
Conviction holders (share of 13F filers)
4.3%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+13.1%
Holder tenure
14.3
Price vs estimated holder cost
+21.5%

Ownership (registered funds)

1 metrics
Index-fund ownership
16.0%

Short interest

3 metrics
Short interest
12.2%
Latest settlement · 5.9 days to cover
Days to cover
5.9d
Short-squeeze score
58 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 744218 CUSIP 15117B202 13F (30d) 101 filings 79 filers Visit website Investor relations